01—Abstract
Summary
Summary of the 8-K filed March 8, 2024. Cited figures are marked; the original filing is the authoritative source.
On March 8, 2024, 3M's Board of Directors approved the planned spin-off of its Health Care business, which will be named Solventum Corporation (NYSE: SOLV).
3M shareholders will receive one Solventum share for every four 3M shares held at the close of business on the March 18, 2024 record date, with the distribution expected before the open of trading on April 1, 2024. The distribution covers 80.1%a of Solventum's outstanding shares; 3M will retain the remaining 19.9%, which it intends to monetize within five years of the spin-off. The distribution is generally intended to be tax-free to U.S. federal income tax purposes for 3M shareholders, and shareholders need not take any action to receive their shares.
Solventum is presented as a leading global healthcare company with $8.2 billionb in 2023 revenue, serving an approximately $93 billion addressable market expected to grow 4-6% annually through 2026. It operates four segments: Medical Surgical, Dental Solutions, Health Information Systems, and Purification & Filtration, and will employ more than 20,000 people under CEO Bryan Hanson and CFO Wayde McMillan. For investors, the key items are the timing of when-issued trading (about March 26), the dual MMM trading markets during the transition window, and the Solventum Investor Day on March 19, 2024.
The filing also reiterates risk factors that remain relevant to 3M's ongoing business, including PFAS-related liabilities, the proposed class-action settlement with U.S. public water systems, and the Combat Arms Earplugs settlement. Completion of the spin-off remains subject to conditions in Solventum's Form 10 registration statement, and the filing notes risks around whether the transaction closes on expected terms and timing, realizes anticipated benefits, and avoids excess dis-synergies or financing costs.
02—Key points
Key Highlights
- Board approved the spin-off of 3M's Health Care business into Solventum Corporation, with distribution expected before trading opens on April 1, 2024.
- Distribution ratio is one Solventum share for every four 3M shares held at the March 18, 2024 record date; cash is paid in lieu of fractional shares.
- 3M will distribute 80.1% of Solventum's outstanding shares and retain 19.9%, which it plans to monetize within five years of the spin-off.
- Solventum reported $8.2 billion in 2023 revenue, serves a roughly $93 billion addressable market, and has applied to list on the NYSE as 'SOLV'.
- Key trading dates: when-issued 'SOLV WI' trading expected around March 26, 2024, with dual 'MMM' and 'MMM WI' markets through March 28, 2024.
- Solventum Investor Day is scheduled for March 19, 2024 in New York City, with a webcast and Q&A with management.
- Distribution is generally intended to be tax-free to U.S. federal income tax purposes for 3M shareholders, and no action is required from shareholders to receive shares.
03—Questions
Frequently Asked Questions
Do I need to do anything to receive Solventum shares?
No. Shareholders of record at the close of business on March 18, 2024 will automatically receive Solventum shares in the distribution, with no payment, surrender, or exchange of 3M shares required. Cash will be paid in lieu of any fractional shares.
How many Solventum shares will I receive?
You will receive one share of Solventum common stock for every four shares of 3M common stock you held at the close of business on March 18, 2024.
When will Solventum begin trading and under what symbol?
When-issued trading is expected to begin on or about March 26, 2024 under 'SOLV WI' on the NYSE. Regular-way trading is expected to begin on April 1, 2024, the distribution date, under 'SOLV'.
What happens to 3M shares if I sell them between the record date and distribution?
From March 26 through March 28, 2024, 3M shares may trade in two markets: 'MMM' (regular-way, with the right to receive Solventum shares) and 'MMM WI' (ex-distribution, without that right). Shareholders who sell before the distribution should check with their broker to confirm whether the sale carries the Solventum entitlement.
Is the spin-off taxable for shareholders?
The distribution is generally intended to be tax-free to 3M shareholders for U.S. federal income tax purposes. Individual tax consequences can vary, so shareholders should consult their own tax advisors.
04—Continue